#204 NephMadness 2020: SGLT2 Inhibitors
Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients.
- Written and Produced by: Hannah R. Abrams
- Cover Art and Infographic by: Hannah R. Abrams
- Hosts: Hannah R Abrams, Matthew Watto MD, FACP
- Editor: Clair Morgan of Nodderly.com (audio), Emi Okamoto MD (written)
- Guests: Harish Seethapathy MD; Matthew Sparks MD; Joel Topf MD
AccessMedicine is the acclaimed online medical resource that features Harrison's Principles of Internal Medicine and more trusted content from the best minds in medicine. Visit AccessMedicine to learn more: http://bit.ly/MHCurbsiders.
Join The Curbsiders!
Pre-med and medical students, we need your help with production of the show! You’ll learn all aspects of podcasting, get to network with national thought leaders and join an amazing global team of Curbsiders. We are especially in need of folks with experience creating video content, developing websites and using social media tools. Application deadline is Friday April 10, 2020. Send an email to email@example.com and include the following:
[ ] A half page on why you’d make a great Curbsider
[ ] A copy of your CV
[ ] Your social media handles on Instagram, Twitter, etc.
[ ] Samples of prior work (e.g. videos, websites, etc.)
- 00:00 Sponsor
- 00:26 Intro, disclaimer, guest bio
- 02:57 Guest one-liner and Pick of the Week: Michael Pollan audiobook on Coffee and Caffeine Addiction
- 03:52 SGLT2i definition, background, and why we now consider CV endpoints in diabetes
- 11:16 Sponsor
- 12:00 Tubuloglomerular feedback; Balloon analogy
- 17:40 Other mechanisms for SGLT2i
- 23:05 Back to the case; Risks from SGLT2i; Counseling and Monitoring
- 34:18 SGLT2i for non-diabetic kidney disease; Possible mechanisms: Joel’s caution against early adoption
- 41:42 SGLT2 inhibitors in kidney transplant
- 45:20 Take home points and picks for the SGLT2 inhibitor region
- 49:50 Outro
Listeners will recognize the different potential mechanisms for SGLT2i mechanisms and the different populations which may derive benefit from treatment.
After listening to this episode listeners will…
- Identify the theorized mechanism by which SGLT2i improve outcomes through their effect on tubuloglomerular feedback and other theorized mechanisms for SGLT2i effects
- Develop a pathophysiological understanding of SGLT2i adverse effects, including acute decrease in GFR and genital infections
- Recognize the potential benefit of using SGLT2i in non-diabetic patients, including for kidney disease, heart failure, and kidney transplant
The Curbsiders report no relevant financial disclosures. Drs. Seethapathy and Sparks report no relevant financial disclosures. Joel Topf lists the following on his blog “I have an ownership stake in a few Davita run dialysis clinics and a vascular access center. Takeda Oncology made a donation to MM4MM the program that is taking me to Mount Everest in 2018.”
Seethapathy H, Abrams HR, Okamoto E, Sparks M, Topf J, Watto MF. “#204 NephMadness 2020: SGLT2 Inhibitors”. The Curbsiders Internal Medicine Podcast. https://thecurbsiders.com/episode-list April 6, 2020.